Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Forecasted Federal grant Posted
- Opportunity number
- RFA-CA-28-002
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications expected due
- Award size
- Up to $300,000
Opportunity facts
- Expected posting
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Health
- Eligible applicants
-
- Small Businesses
- Non-501(c)(3) Nonprofits
- Higher Education Inst. (Private)
- Tribal Organizations (Not Federally Recognized)
- Independent School Districts
- For Profit Organizations
- Public or Indian Housing Auth.
- State Governments
- Tribal Governments (Federally Recognized)
- Higher Education Inst. (Public)
- County Governments
- City/Township Governments
- Special District Governments
- Other
- 501(c)(3) Nonprofits
- Points of contact
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Cancer Institute solicits R33 grant applications by November 10, 2026, proposing exploratory research for further development and validation of emerging technologies in cancer research and clinical care, with clinical trial applications explicitly not allowed. Eligible applicants include small businesses, nonprofits (both 501(c)(3) and non-501(c)(3)), higher education institutions (public and private), tribal organizations (federally and non-federally recognized), state and local governments, special district governments, for-profit organizations, faith-based and community-based organizations, regional organizations, eligible federal agencies, U.S. territories and possessions, and non-domestic entities.
Applications must demonstrate that major feasibility gaps have been overcome through preliminary data, with technology or methodology requiring further development, enhancement, optimization, and rigorous validation for adoption by the research community. Suitable applications accelerate or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, or epidemiology. Eligible technologies include advanced molecular and cellular analysis platforms, multi-omic and spatial profiling methods, imaging and sensing technologies, immuno-engineering approaches, and innovations in biospecimen processing, modeling, and quality assessment. Technologies with new or significantly improved capabilities to measure, analyze, model, or interrogate cancer-related systems qualify, provided the novelty centers on technical advancement rather than application of existing technologies to new clinical targets or biological questions.
This opportunity is part of the National Cancer Institute's Innovative Molecular Analysis Technologies (IMAT) Program, assigned to the Cancer Detection and Diagnosis Research program under CFDA 93.394. Peer review assesses scientific merit, technical adequacy of experimental design, investigator competency, facility adequacy, budget necessity, and relevance to program objectives. Grants and cooperative agreements are funded on a competitive basis annually, with selection determined by scientific merit, program relevance, program balance, and alignment with NCI and NIH strategic priorities.
Forecast synopsis
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies for cancer research or clinical care. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development, enhancements, optimizations, and rigorous technical validation to encourage adoption by the research community.
Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, and/or epidemiology. Projects that are in-scope include technologies with new or significantly improved technical capabilities to measure, analyze, model, or interrogate cancer-related systems. These may include, but are not limited to, advanced molecular and cellular analysis platforms, multi-omic and spatial profiling methods, imaging and sensing technologies, immuno-engineering approaches, and innovations in biospecimen processing, modeling, and quality assessment. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer applications. Projects proposing application of existing technologies where the novelty resides in the clinical target or biological question being pursued are not appropriate for this solicitation.
This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity